SEC Form 4 · accession 0001140361-17-009668
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — President, Worldwide R&D
Period of report
Feb 24, 2017
Accepted (ET)
Feb 28, 2017 · 4:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3,F2 | Feb 24, 2017 | A | 14,564 | $0.00 | A | 128,442 | D | |
| Common StockF4 | Feb 24, 2017 | M | 15,000 | $26.49 | A | 143,442 | D | |
| Common StockF4,F5 | Feb 24, 2017 | S | 15,000 | $87.99 | D | 128,442 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F4,F6 | $26.49 | Feb 24, 2017 | M | 15,000 | D | Nov 12, 2011 | May 11, 2021 | Common Stock | 15,000 | 20,225 | D |
Explanation of responses
- F1Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
- F2Represents the total number of RSUs earned pursuant to a calculation based on the level of the Issuer's total adjusted revenues for the fiscal year ended December 31, 2016, as certified by its audited financials, set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan.
- F3Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2017, 2018 and 2019, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events.
- F4Trade made pursuant to a 10b5-1 plan executed on May 12, 2016.
- F5All shares were sold at the same price.
- F6Reflects the number of stock options outstanding after the transaction from this specific stock option grant.